Practical modifications to the Time-to-Event Continual Reassessment Method for phase I cancer trials with fast patient accrual and late-onset toxicities

Por Polley, Mei-Yin C.
Publicado em 2011

Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology

Por Polley, Mei-Yin C., Cheung, Ying Kuen
Publicado no JCO Precis Oncol (2019)

Development of omics-based clinical tests for prognosis and therapy selection: The challenge of achieving statistical robustness and clinical utility

Por McShane, Lisa M., Polley, Mei-Yin C.
Publicado no Clin Trials (2013)

Phase III Precision Medicine Clinical Trial Designs That Integrate Treatment and Biomarker Evaluation

Por Polley, Mei-Yin C., Korn, Edward L., Freidlin, Boris
Publicado no JCO Precis Oncol (2019)

Randomized Phase II Trial Designs With Biomarkers

Por Freidlin, Boris, McShane, Lisa M., Polley, Mei-Yin C., Korn, Edward L.
Publicado em 2012

Two-Stage Adaptive Cutoff (TACO) Design for Building and Validating a Prognostic Biomarker Signature

Por Polley, Mei-Yin C., Polley, Eric C., Huang, Erich P., Freidlin, Boris, Simon, Richard
Publicado no Stat Med (2014)

Comparison of confidence interval methods for an intra-class correlation coefficient (ICC)

Por Ionan, Alexei C, Polley, Mei-Yin C, McShane, Lisa M, Dobbin, Kevin K
Publicado no BMC Med Res Methodol (2014)

Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide

Por Polley, Mei-Yin C., Lamborn, Kathleen R., Chang, Susan M., Butowski, Nicholas, Clarke, Jennifer L., Prados, Michael
Publicado em 2010

Conditional Probability of Survival in Patients With Newly Diagnosed Glioblastoma

Por Polley, Mei-Yin C., Lamborn, Kathleen R., Chang, Susan M., Butowski, Nicholas, Clarke, Jennifer L., Prados, Michael
Publicado em 2011

Statistical and Practical Considerations for Clinical Evaluation of Predictive Biomarkers

Por Polley, Mei-Yin C., Freidlin, Boris, Korn, Edward L., Conley, Barbara A., Abrams, Jeffrey S., McShane, Lisa M
Publicado em 2013

Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme(†)

Por Khayal, Inas S., Polley, Mei-Yin C., Jalbert, Llewellyn, Elkhaled, Adam, Chang, Susan M., Cha, Soonmee, Butowski, Nicholas A., Nelson, Sarah J.
Publicado em 2010

Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM

Por Srinivasan, Radhika, Phillips, Joanna J., VandenBerg, Scott R., Polley, Mei-Yin C., Bourne, Gabriela, Au, Alvin, Pirzkall, Andrea, Cha, Soonmee, Chang, Susan M., Nelson, Sarah J.
Publicado em 2010

Mass Cytometry Analysis Reveals that Specific Intratumoral CD4(+) T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma

Por Yang, Zhi-Zhang, Jin Kim, Hyo, Villasboas, Jose C., Price-Troska, Tammy, Jalali, Shahrzad, Wu, Hongyan, Luchtel, Rebecca A., Polley, Mei-Yin C., Novak, Anne J., Ansell, Stephen M.
Publicado no Cell Rep (2019)

Combined Oncogenic BRAF Mutation and CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas

Por Schiffman, Joshua D., Hodgson, J. Graeme, Vandenberg, Scott R., Flaherty, Patrick, Polley, Mei-Yin C., Yu, Mamie, Fisher, Paul G., Rowitch, David H., Ford, James M., Berger, Mitchel S., Ji, Hanlee, Gutmann, David H., James, C. David
Publicado em 2010

Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration

Por McShane, Lisa M, Cavenagh, Margaret M, Lively, Tracy G, Eberhard, David A, Bigbee, William L, Williams, P Mickey, Mesirov, Jill P, Polley, Mei-Yin C, Kim, Kelly Y, Tricoli, James V, Taylor, Jeremy MG, Shuman, Deborah J, Simon, Richard M, Doroshow, James H, Conley, Barbara A
Publicado em 2013

Criteria for the use of omics-based predictors in clinical trials

Por McShane, Lisa M., Cavenagh, Margaret M., Lively, Tracy G., Eberhard, David A., Bigbee, William L., Williams, P. Mickey, Mesirov, Jill P., Polley, Mei-Yin C., Kim, Kelly Y., Tricoli, James V., Taylor, Jeremy M. G., Shuman, Deborah J., Simon, Richard M., Doroshow, James H., Conley, Barbara A.
Publicado em 2013

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

Por Schöder, Heiko, Polley, Mei-Yin C., Knopp, Michael V., Hall, Nathan, Kostakoglu, Lale, Zhang, Jun, Higley, Howard R., Kelloff, Gary, Liu, Heshan, Zelenetz, Andrew D., Cheson, Bruce D., Wagner-Johnston, Nina, Kahl, Brad S., Friedberg, Jonathan W., Hsi, Eric D., Leonard, John P., Schwartz, Lawrence H., Wilson, Wyndham H., Bartlett, Nancy L.
Publicado no Blood (2020)

An International Ki67 Reproducibility Study

Por Polley, Mei-Yin C., Leung, Samuel C. Y., McShane, Lisa M., Gao, Dongxia, Hugh, Judith C., Mastropasqua, Mauro G., Viale, Giuseppe, Zabaglo, Lila A., Penault-Llorca, Frédérique, Bartlett, John M.S., Gown, Allen M., Symmans, W. Fraser, Piper, Tammy, Mehl, Erika, Enos, Rebecca A., Hayes, Daniel F., Dowsett, Mitch, Nielsen, Torsten O.
Publicado em 2013

A clinical calculator to predict disease outcomes in women with triple-negative breast cancer

Por Polley, Mei-Yin C., Leon-Ferre, Roberto A., Leung, Samuel, Cheng, Angela, Gao, Dongxia, Sinnwell, Jason, Liu, Heshan, Hillman, David W., Eyman-Casey, Abraham, Gilbert, Judith A., Negron, Vivian, Boughey, Judy C., Liu, Minetta C., Ingle, James N., Kalari, Krishna, Couch, Fergus, Carter, Jodi M., Visscher, Daniel W., Nielsen, Torsten O., Goetz, Matthew P.
Publicado no Breast Cancer Res Treat (2021)

Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients

Por Norton, Nadine, Youssef, Bahaaeldin, Hillman, David W., Nassar, Aziza, Geiger, Xochiquetzal J., Necela, Brian M., Liu, Heshan, Ruddy, Kathryn J., Polley, Mei-Yin C., Ingle, James N., Couch, Fergus J., Perez, Edith A., Liu, Minetta C., Carter, Jodi M., Leon-Ferre, Roberto A., Boughey, Judy C., Somers, Elizabeth B., Kalari, Krishna R., Visscher, Daniel W., Goetz, Matthew P., Knutson, Keith L.
Publicado no NPJ Breast Cancer (2020)